Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in Oncolytic Virus Cancer Therapy Research. Learn more about our innovative pipeline today! @ Oncolytic Virus Cancer Therapy Pipeline Outlook
Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report
In June 2025, Replimune Inc. conducted a study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Promising Oncolytic Virus Cancer Therapy Pipeline Therapies such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.
Stay informed about the cutting-edge advancements in Oncolytic Virus Cancer Therapy treatments. Download for updates and be a part of the revolution in Oncology Care @ Oncolytic Virus Cancer Therapy Clinical Trials Assessment
Oncolytic Virus Cancer Therapy Emerging Drugs Profile
Olvi-Vec: Genelux Corporation
Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
CAN-2409: Candel Therapeutics
CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer.
CG0070: CG Oncology
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer.
Pelareorep: Oncolytics Biotech
Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer.
ParvOryx: Oryx GmbH
ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer.
SND005: Jiangsu Sinorda Biomedicine
SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients.
VCN-01: VCN Biosciences
VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.
The Oncolytic Virus Cancer Therapy Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.
Learn more about Oncolytic Virus Cancer Therapy Drugs opportunities in our groundbreaking Oncolytic Virus Cancer Therapy research and development projects @ Oncolytic Virus Cancer Therapy Unmet Needs
Oncolytic Virus Cancer Therapy Companies
Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intranasal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as
Oncolytic Virus
Discover the latest advancements in Oncolytic Virus Cancer Therapy treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives
Scope of the Oncolytic Virus Cancer Therapy Pipeline Report
Coverage- Global
Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Oncolytic Virus Cancer Therapy Pipeline Therapies- Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.
Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Oncolytic Virus Cancer Therapy Pipeline on our website @ Oncolytic Virus Cancer Therapy Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Oncolytic Virus Cancer Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Oncolytic Virus Cancer Therapy– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Olvi-Vec: Genelux Corporation
Mid Stage Products (Phase II)
SND005: Jiangsu Sinorda Biomedicine
Early Stage Products (Phase I/II)
AloCelyvir: Orgenesis
Early Stage Products (Phase I)
VCN-01: VCN Biosciences
Preclinical and Discovery Stage Products
SynOV 1.3: Beijing Syngentech
Inactive Products
Oncolytic Virus Cancer Therapy Key Companies
Oncolytic Virus Cancer Therapy Key Products
Oncolytic Virus Cancer Therapy- Unmet Needs
Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
Oncolytic Virus Cancer Therapy Analyst Views
Oncolytic Virus Cancer Therapy Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
22 minutes ago
- Globe and Mail
Market Analysis: July 23, 2025
Global Markets Canadian Markets Canadian markets edged higher on Wednesday, showing resilience even as both gold and oil prices remained under pressure. Canadian prime minister, Mark Carney, stated that the country would not settle for a 'bad deal' regarding U.S. tariffs. With the August 1st deadline for new U.S. tariffs looming, negotiations between the two nations appear stalled, casting doubt on whether a last-minute agreement can be reached. American Markets U.S. stocks climbed after news broke that the United States and Japan had reached a trade agreement. The deal, seen as favorable for Japanese automakers, lifted sentiment broadly across global markets. Google and Tesla is set to report earnings after the closing bell. For Tesla, it is an event highly anticipated by investors given the stock's recent volatility and questions surrounding the company's margins, growth strategy, and delivery performance. European Markets European stocks moved higher on optimism that a similar trade deal could be struck between the U.S. and European Union, especially one that benefits European carmakers. Automakers led the gains across major indices in Europe. Shares of German software giant SAP dropped, despite the company reporting a strong quarterly performance. Investors were disappointed that SAP chose to maintain its full-year guidance instead of raising it, dampening enthusiasm. In the UK, stocks reached yet another all-time high, driven in part by strong performances from mining and industrial sectors. A record number of UK-listed companies issued profit warnings in the second quarter, raising red flags about the upcoming earnings season and potentially signaling broader economic challenges. Corporate News Alibaba Group Holding Ltd: Launched Qwen3-Coder, its most advanced open-source AI coding model. Designed for complex programming tasks, it's strong in autonomous coding workflows. Inc: Acquired Bee, a startup making AI-enabled wristbands that transcribe and summarize conversations. America Movil SAB de CV: Swung to a Q2 profit of 22.28 billion pesos, driven by 11 billion pesos in FX gains and reduced financing costs. Revenue rose 14% to $12.46B. AT&T Inc: Beat Q2 profit estimates and added 401K wireless subscribers. Plans to invest $3.5B in fiber network using tax savings and raised free cash flow forecast for 2026–27 by $1B. Baker Hughes Co: Beat Q2 estimates with EPS of $0.63 vs. $0.56 expected. Gas tech orders up 28%, though overall revenue declined 3% YoY to $6.91B due to weaker drilling activity. Boeing Co: Offered union workers a 20% wage increase over 4 years, a $5K bonus, and more leave in its latest contract proposal. Capital One Financial Corp: Q2 profit rose to $2.77B ($5.48/share) from $1.21B. Interest income surged 32.5% to $10B; loan loss provisions jumped to $11.43B. Charter Communications Inc: Partnering with Comcast to launch an MVNO using T-Mobile's 5G network for business customers. Chubb Ltd: Q2 core operating income rose 13% to $2.48B; record investment income ($1.57B) and underwriting performance. Combined ratio improved to 85.6%. Coca-Cola Co: Jefferies raised target price to $84 (from $83) due to easing forex headwinds. Comcast Corp: Partnering with Charter on an MVNO service for business customers using T-Mobile's network. ConocoPhillips: In advanced talks to sell Oklahoma assets to Stone Ridge Energy for ~$1.3B. Corpay Inc: To acquire UK-based Alpha Group for $2.2B, expanding into investment fund client segment. CoStar Group Inc: Raised annual revenue forecast (now $3.14–$3.16B) due to strong traffic and 65% quarterly jump in net new bookings. Dassault Aviation: Raised concerns about the future of a trilateral fighter jet project due to disputes with Airbus over program control. Delta Air Lines Inc: Facing scrutiny from U.S. senators over potential AI-driven ticket pricing. Denies using personal data for individualized fares. Enphase Energy Inc: Forecast Q3 revenue of $330M–$370M, missing expectations. Q2 profit beat estimates despite gross margin pressure from Trump-era tariffs. Equinor ASA: Q2 pre-tax profit dropped 13% YoY to $6.54B, in line with expectations. Maintains 2025 production and capex guidance. EQT Corp: Q2 profit beat, raised production forecast to 2,300–2,400 Bcfe from 2,200–2,300. Benefits from higher gas prices and Olympus Energy acquisition. Ford Motor Co: Industry group opposes Japan trade deal that lowers tariffs while maintaining higher ones on Canadian/Mexican autos. Galaxy Digital Holdings Ltd: Jefferies initiates with a 'Buy' rating, $35 target; sees upside from crypto regulation and AI data center demand. General Motors Co: Concerned about trade deal that gives Japan a tariff advantage over North American automakers. Hilton Worldwide Holdings Inc: Raised full-year adjusted profit forecast to $7.83–$8/share, from $7.76–$7.94. Q2 EPS rose to $2.20 from $1.91. Infosys Ltd: Narrowed annual growth forecast to 1%–3%. Q1 sales rose 7.5% to $4.89B; net profit rose 8.7% to 69.21B rupees. Intuitive Surgical Inc: Beat Q2 estimates with EPS of $2.19 (vs. $1.92 expected); lifted gross margin forecast and expects lower tariff impact. Jefferies raised target to $550 (from $530). Lockheed Martin Corp: Jefferies cut target to $460 from $500 after a $1.6B pretax loss tied to a classified aeronautics program. Microsoft Corp: Initial SharePoint patch failed to fix major vulnerability exploited by Chinese groups. Released additional patches afterward. Morgan Stanley: Under FINRA investigation for weak AML client screening across its wealth and institutional units. PayPal Holdings Inc: Launched PayPal World for cross-border payments, in partnership with India's UPI, Mercado Pago, Tenpay Global, and Venmo. SAP SE: Q2 sales and earnings rose, but stock fell as SAP kept FY guidance unchanged. Free cash flow jumped 83% to €2.36B, beating expectations. TE Connectivity PLC: Beat Q3 estimates and issued upbeat Q4 guidance. Tariff impact was half of expected (1.5% vs. 3%). Forecast Q4 revenue ~$4.55B. Texas Instruments Inc: Q3 guidance missed expectations. Cited tariff/geopolitical issues. Jefferies raised price target to $185 from $155. UniCredit (Italy): Withdrew €15B bid for Banco BPM, blaming government interference. Vale SA: Q2 iron ore output rose 3.7% to 83.6M tons. Sales fell 3.1% YoY, but strong performance from S11D and Brucutu mines supports 2025 goals. Woodside Energy Group Ltd: Q2 revenue rose 8% to $3.28B, helped by Senegal's Sangomar project. Took write-downs on hydrogen and old offshore assets. Lowered production costs to $8–$8.50/boe.
Globe and Mail
22 minutes ago
- Globe and Mail
EU heading toward 15% tariff deal with Washington, diplomats say
The European Union is heading toward a trade deal with Washington that would result in a broad 15-per-cent tariff on EU goods imported into the U.S., avoiding a harsher 30-per-cent levy slated to be implemented from Aug. 1, two EU diplomats said on Wednesday. The rate, which could also extend to cars, would mirror the framework agreement the United States struck with Japan. Officials from the European Commission, which negotiates trade deals on behalf of the 27-nation bloc, briefed EU envoys on the state of talks with their U.S. counterparts. U.S. President Donald Trump would ultimately make any final decision on a deal, however. Under the outlines of the potential deal, the 15-per-cent rate could apply to sectors including cars and pharmaceuticals and would not be added to long-standing U.S. duties, which average just under 5 per cent. There could also be concessions for sectors like aircraft, lumber as well as some medicines and agricultural products, which would not face tariffs, the diplomats said. Washington does not, however, appear willing to lower its current 50-per-cent tariff on steel, they said. The Commission said earlier on Wednesday that its primary focus was to achieve a negotiated outcome to avert the threatened 30-per-cent tariffs. At the same time it planned to submit counter-tariffs on €93-billion ($174.5-billion) worth of U.S. goods to EU members for approval. A vote is expected on Thursday, though no measures would be imposed until August 7. Germany supported the EU readying countermeasures, a government representative said. If Trump's 30-per-cent tariffs are implemented, EU diplomats also said there was broad support among European governments to activate wide-ranging so-called'anti-coercion' measures, which would allow the bloc to target U.S. services and other sectors. The EU appears to be following in the footsteps of Japan, whose agreement with the United States is the most significant Trump has struck since launching his tariff offensive in April. European shares climbed around 1 per cent, led by automobile stocks, following the U.S.-Japan announcement. One stand-out feature of that deal was that the same 15% rate applies to cars, compared to the current U.S. tariff of 27.5 per cent, something the EU may want for its own auto exports. The U.S. imported vehicles and automotive parts valued at more than US$55-billion from Japan last year. EU exports were €47.3-billion ($75.7-billion). Far fewer U.S. cars were sold into the EU or Japanese markets. EU officials say Washington has shown little sign of budging on car tariffs, but the Japan deal could hint at flexibility. 'Whatever the Japanese got will become the minimum for the EU negotiating objectives,' said Simon Evenett, professor of geopolitics and strategy at IMD Business School.
Globe and Mail
22 minutes ago
- Globe and Mail
Palantir's Current Valuation: Stretched or Fully Justified?
Palantir Technologies PLTR has emerged as one of the most talked-about names in the S&P 500, and not just for what it does, but for what investors are willing to pay for it. With a market capitalization of $358 billion, it now surpasses giants like Coca-Cola and Bank of America. Yet, when viewed through a valuation lens, Palantir stands alone in its league. Its trailing 12-month price-to-earnings ratio exceeds 640X, and its forward 12-month multiple hovers above 225X. Even more striking is its enterprise value relative to forward 12-month revenue of more than 78X, a level rarely seen, even during the most exuberant periods in market history. By that metric, Palantir looks far more expensive than nearly every other established U.S. stock over the past two decades. Such elevated valuations raise the bar for future performance. For a company trading at these levels, expectations around revenue acceleration, margin expansion, and long-term scalability must not only be met; they must be exceeded. Even minor disappointments can trigger sharp corrections as multiples revert toward historical norms. Companies in the past that reached these kinds of revenue multiples — often 30x or higher — eventually faced tough questions about sustainability. Investor optimism alone is rarely enough to sustain prices when fundamentals don't keep up. The pattern is hard to ignore. When companies reach 30x sales or more, they often enter what is viewed as the 'bubble zone,' a place where expectations are sky-high and hard to maintain. Revenue growth typically slows, forecasts get downgraded and valuations eventually compress. In the short term, momentum can mask this risk, but over time, gravity tends to take hold. In conclusion, Palantir's valuation not only defies market norms but also places it well beyond even the exuberance seen in past bubbles. Unless its performance can defy history, the risk of multiple compression looms large. Investors should tread carefully. Stable Defense Alternatives to Palantir As PLTR's valuation moves higher, Lockheed Martin LMT and RTX Corporation RTX offer more grounded defense exposure. Lockheed Martin, with its massive defense contracts, provides steady cash flow and less volatility than PLTR. Its trailing 12-month price-to-earnings ratio is below 18X, and its forward 12-month multiple is just above 14X. Lockheed Martin continues to benefit from global rearmament while trading at modest earnings multiples. Similarly, RTX shines through missile systems. RTX's defense backlog, like LMT's, underscores its stability. Its trailing 12-month price-to-earnings ratio is below 44X, and its forward 12-month multiple is just above 23X. PLTR's Price Performance, Estimates The stock has surged a whopping 97% year to date, significantly outperforming the industry 's 19% rally. The Zacks Consensus Estimate for PLTR's earnings has remained unchanged over the past 30 days. PLTR stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lockheed Martin Corporation (LMT): Free Stock Analysis Report RTX Corporation (RTX): Free Stock Analysis Report Palantir Technologies Inc. (PLTR): Free Stock Analysis Report
